An siRNA, wherein the siRNA comprises a sense strand and an antisense strand, and each nucleotide in the siRNA is independently a modified or unmodified nucleotide, wherein the sense strand comprises a nucleotide sequence I, and the antisense strand comprises a nucleotide sequence II;
- the nucleotide sequence I and the nucleotide sequence II are at least partly reverse complementary to form a double-stranded region;
- and the nucleotide sequence I and the nucleotide sequence II are selected from a group of sequences shown in the following i)-vi):
- i) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:1;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:2:
- (SEQ ID NO:
- 1)
- 5′-AAAGUAACAACCAGUUUGZ1-3′;
- (SEQ ID NO:
- 2)
- 5′-Z2CAAACUGGUUGUUACUUU-3′,
- wherein, Z1 is U, and Z2 is A;
- and
- the nucleotide sequence I comprises a nucleotide Z3 at a corresponding site to Z1, the nucleotide sequence II comprises a nucleotide Z4 at a corresponding site to Z2, and Z4 is the first nucleotide from the 5′ terminal of the antisense strand;
- ii) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 61;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 62:
- (SEQ ID NO:
- 61)
- 5′-AUUGAACUUUCGAAUUACZ5-3′;
- (SEQ ID NO:
- 62)
- 5′-Z6GUAAUUCGAAAGUUCAAU-3′,
- wherein, Z5 is C, and Z6 is G;
- and
- the nucleotide sequence I comprises a nucleotide Z7 at a corresponding site to Z5, the nucleotide sequence II comprises a nucleotide Z8 at a corresponding site to Z6, and Z8 is the first nucleotide from the 5′ terminal of the antisense strand;
- iii) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 121;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 122:
- (SEQ ID NO:
- 121)
- 5′-UCGAAUUACCUACUCAAUZ9-3′;
- (SEQ ID NO:
- 122)
- 5′-Z10AUUGAGUAGGUAAUUCGA-3′,
- wherein, Z9 is U, and Z10 is A;
- and
- the nucleotide sequence I comprises a nucleotide Z11 at a corresponding site to Z9, the nucleotide sequence II comprises a nucleotide Z12 at a corresponding site to Z10, and Z12 is the first nucleotide from the 5′ terminal of the antisense strand;
- iv) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 181;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 182:
- (SEQ ID NO:
- 181)
- 5′-GAUAAUGCAUACAUCGAUZ13-3′;
- (SEQ ID NO:
- 182)
- 5′-Z14AUCGAUGUAUGCAUUAUC-3′,
- wherein, Z13 is A, and Z14 is U;
- and
- the nucleotide sequence I comprises a nucleotide Z15 at a corresponding site to Z13, the nucleotide sequence II comprises a nucleotide Z1e at a corresponding site to Z14, and Z1s is the first nucleotide from the 5′ terminal of the antisense strand;
- v) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 241;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 242:
- (SEQ ID NO:
- 241)
- 5′-GAAUAACGCAACUUUCUAZ17-3′;
- (SEQ ID NO:
- 242)
- 5′-Z18UAGAAAGUUGCGUUAUUC-3′,
- wherein, Z17 is U, and Z18 is A;
- and
- the nucleotide sequence I comprises a nucleotide Z19 at a corresponding site to Z17, the nucleotide sequence II comprises a nucleotide Z20 at a corresponding site to Z13, and Z20 is the first nucleotide from the 5′ terminal of the antisense strand;
- vi) the nucleotide sequence I has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 301;
- and the nucleotide sequence II has the same length as and no more than three nucleotide differences from the nucleotide sequence shown in SEQ ID NO:
- 302:
- (SEQ ID NO:
- 301)
- 5′-AACUUUCUAUUUCAAGAUZ21-3′;
- (SEQ ID NO:
- 302)
- 5′-Z22AUCUUGAAAUAGAAAGUU-3′,
- wherein, Z21 is U, and Z22 is A;
- and
- the nucleotide sequence I comprises a nucleotide Z23 at a corresponding site to Z21, the nucleotide sequence II comprises a nucleotide Z24 at a corresponding site to Z22, and Z24 is the first nucleotide from the 5′ terminal of the antisense strand.